Finance Industry Rallies to Fight Melanoma
Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event, sponsored annually in New York City by the Melanoma Research Alliance (MRA) has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities – all gathered together in response to melanoma.
Polka Dot Mama Melanoma Foundation Launches Shade Shuttle Bus Tour
By Pamela Goldsmith, MRA Director of Communications | 2 April 2017
Taking her advocacy to the next level, Tracy Callahan, along with the Tara Miller Melanoma Foundation, is about to launch Shade Shuttle, a multi-state bus tour dedicated to raising awareness and educating the community about melanoma.
Trena's Story: An African-American Retiree's Journey with Melanoma
8 June 2016 In Melanoma Stories
“Trena, you have melanoma and you are going to lose your toe. “ WHAT?!?! I am a Black woman in her sixties—that is crazy!!
Approaches to Neoadjuvant Treatment in Melanoma: A Public Workshop Organized by the FDA and MRA
13 November 2019
On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.
Spotlight on MRA’s Ninth Annual Scientific Retreat
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science
In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.
Melanoma Prevention: The Latest Advances & Future Directions
During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?
MRA’s Young Investigator Program: Bringing New Talent & Novel Ideas for Research Forward
In February, at the Ninth Annual MRA Scientific Retreat, a Young Investigator Breakfast brought together scores of past and current MRA Young Investigators where I connected with one of MRA’s first young investigators, Dr. Timothy Bullock.
The Power of Combination Therapies: One Patient’s Road to Remission
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 28 February 2017 In Science, Treatment
Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.
Melanoma 2016 — the Year in Review
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News
In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.